Analyst Price Targets — NKTR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 22, 2026 9:16 am | Edward Nash | Canaccord Genuity | $153.00 | $68.67 | TheFly | Nektar initiated with a Buy at Canaccord |
| May 11, 2026 11:51 am | Martin Fan | Wedbush | $80.00 | $81.89 | TheFly | Nektar price target lowered to $80 from $95 at Wedbush |
| May 8, 2026 11:07 am | Yasmeen Rahimi | Piper Sandler | $192.00 | $83.37 | TheFly | Nektar price target raised to $192 from $105 at Piper Sandler |
| April 21, 2026 12:50 pm | — | Wedbush | $95.00 | $101.64 | TheFly | Nektar price target raised to $95 from $70 at Wedbush |
| April 20, 2026 2:33 pm | — | H.C. Wainwright | $185.00 | $106.75 | TheFly | Nektar price target raised to $185 from $165 at H.C. Wainwright |
| March 13, 2026 4:39 pm | Jay Olson | Oppenheimer | $140.00 | $73.27 | StreetInsider | Nektar Therapeutics (NKTR) PT Raised to $140 at Oppenheimer |
| February 10, 2026 5:17 pm | — | BTIG | $151.00 | $52.00 | TheFly | Nektar price target raised to $151 from $118 at BTIG |
| February 10, 2026 2:16 pm | — | H.C. Wainwright | $165.00 | $52.62 | TheFly | Nektar price target raised to $165 from $135 at H.C. Wainwright |
| January 26, 2026 1:56 pm | Yasmeen Rahimi | Piper Sandler | $105.00 | $36.35 | StreetInsider | Piper Sandler on Nektar Therapeutics (NKTR): 'We See a Substantial Opportunity Into These De-Risked Data' |
| December 16, 2025 5:48 pm | — | H.C. Wainwright | $135.00 | $51.17 | TheFly | Nektar price target raised to $135 from $120 at H.C. Wainwright |
Latest News for NKTR
SAN FRANCISCO, Aug. 28, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on August 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 25,200 shares of its common stock and 5,000 restricted stock units (RSUs) to eleven newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025…
REZOLVE-AD study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2w First large, placebo-controlled trial to support T-reg modulation as a clinical mechanism for immunoregulation of chronic inflammatory disease Findings support the continued development of rezpegaldesleukin in the ongoing Phase 3 ZENITH AD clinical program SAN…
Nektar Therapeutics maintains a Strong Buy rating, driven by REZPEG's late-stage development in atopic dermatitis [AD] and alopecia areata [AA]. The Phase 3 ZENITH AD program is underway, with three pivotal studies targeting moderate-to-severe AD subpopulations; topline data is expected mid-2028. REZPEG's differentiated mechanism aims for long-term disease control and safety advantages over current AD therapies,…
NKTR's Q2 earnings beat estimates, but revenues fall short. Investor focus stays on rezpeg as late-stage studies advance in autoimmune diseases.
Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NKTR.
U.S. House Trading
No House trades found for NKTR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.